D
Akero Therapeutics, Inc.
AKRO
$35.67
$0.8452.43%
D
Sell
3/14/2023Downgrade
Akero Therapeutics, Inc. (AKRO) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
Akero Therapeutics, Inc. (AKRO) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/23/2023Upgraded
Akero Therapeutics, Inc. (AKRO) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index, volatility index and valuation index.
Akero Therapeutics, Inc. (AKRO) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index, volatility index and valuation index.
D
Sell
2/8/2023Downgrade
Akero Therapeutics, Inc. (AKRO) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index and growth index. EBIT declined 30.79% from -$27.59M to -$36.09M, operating cash flow declined 26.22% from -$19.51M to -$24.62M, and earnings per share declined from -$0.7745 to -$0.9193.
Akero Therapeutics, Inc. (AKRO) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index and growth index. EBIT declined 30.79% from -$27.59M to -$36.09M, operating cash flow declined 26.22% from -$19.51M to -$24.62M, and earnings per share declined from -$0.7745 to -$0.9193.
D
Sell
9/13/2022Upgraded
Akero Therapeutics, Inc. (AKRO) was upgraded to D from D- on 9/13/2022 due to an increase in the volatility index, total return index and solvency index.
Akero Therapeutics, Inc. (AKRO) was upgraded to D from D- on 9/13/2022 due to an increase in the volatility index, total return index and solvency index.
D
Sell
5/31/2022Downgrade
Akero Therapeutics, Inc. (AKRO) was downgraded to D- from D on 5/31/2022 due to a decline in the total return index and volatility index.
Akero Therapeutics, Inc. (AKRO) was downgraded to D- from D on 5/31/2022 due to a decline in the total return index and volatility index.
D
Sell
5/16/2022Upgraded
Akero Therapeutics, Inc. (AKRO) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Akero Therapeutics, Inc. (AKRO) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Akero Therapeutics, Inc. (AKRO) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
Akero Therapeutics, Inc. (AKRO) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/6/2022Upgraded
Akero Therapeutics, Inc. (AKRO) was upgraded to D from D- on 5/6/2022 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.9294 to -$0.7436, EBIT increased 19.69% from -$32.44M to -$26.05M, and operating cash flow increased 14.31% from -$26.7M to -$22.88M.
Akero Therapeutics, Inc. (AKRO) was upgraded to D from D- on 5/6/2022 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.9294 to -$0.7436, EBIT increased 19.69% from -$32.44M to -$26.05M, and operating cash flow increased 14.31% from -$26.7M to -$22.88M.
D
Sell
5/5/2022Upgraded
Akero Therapeutics, Inc. (AKRO) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
Akero Therapeutics, Inc. (AKRO) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
Akero Therapeutics, Inc. (AKRO) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.
Akero Therapeutics, Inc. (AKRO) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.
D
Sell
4/18/2022Downgrade
Akero Therapeutics, Inc. (AKRO) was downgraded to D- from D on 4/18/2022 due to a decline in the total return index and volatility index.
Akero Therapeutics, Inc. (AKRO) was downgraded to D- from D on 4/18/2022 due to a decline in the total return index and volatility index.
D
Sell
3/21/2022Upgraded
Akero Therapeutics, Inc. (AKRO) was upgraded to D from D- on 3/21/2022 due to an increase in the volatility index and valuation index.
Akero Therapeutics, Inc. (AKRO) was upgraded to D from D- on 3/21/2022 due to an increase in the volatility index and valuation index.
D
Sell
3/2/2022Downgrade
Akero Therapeutics, Inc. (AKRO) was downgraded to D- from D on 3/2/2022 due to a noticeable decline in the volatility index, growth index and total return index. Operating cash flow declined 82.77% from -$14.61M to -$26.7M, EBIT declined 33.2% from -$24.35M to -$32.44M, and earnings per share declined from -$0.6979 to -$0.9294.
Akero Therapeutics, Inc. (AKRO) was downgraded to D- from D on 3/2/2022 due to a noticeable decline in the volatility index, growth index and total return index. Operating cash flow declined 82.77% from -$14.61M to -$26.7M, EBIT declined 33.2% from -$24.35M to -$32.44M, and earnings per share declined from -$0.6979 to -$0.9294.
D
Sell
11/15/2021Upgraded
Akero Therapeutics, Inc. (AKRO) was upgraded to D from D- on 11/15/2021 due to a noticeable increase in the growth index and total return index. Operating cash flow increased 27.09% from -$20.03M to -$14.61M, earnings per share increased from -$0.8311 to -$0.6979, and EBIT increased 15.93% from -$28.97M to -$24.35M.
Akero Therapeutics, Inc. (AKRO) was upgraded to D from D- on 11/15/2021 due to a noticeable increase in the growth index and total return index. Operating cash flow increased 27.09% from -$20.03M to -$14.61M, earnings per share increased from -$0.8311 to -$0.6979, and EBIT increased 15.93% from -$28.97M to -$24.35M.
D
Sell
11/8/2021Downgrade
Akero Therapeutics, Inc. (AKRO) was downgraded to D- from D on 11/8/2021 due to a major decline in the growth index, valuation index and solvency index. EBIT declined 91.47% from -$15.13M to -$28.97M, earnings per share declined from -$0.4343 to -$0.8311, and the quick ratio declined from 24.66 to 13.98.
Akero Therapeutics, Inc. (AKRO) was downgraded to D- from D on 11/8/2021 due to a major decline in the growth index, valuation index and solvency index. EBIT declined 91.47% from -$15.13M to -$28.97M, earnings per share declined from -$0.4343 to -$0.8311, and the quick ratio declined from 24.66 to 13.98.
D
Sell
7/29/2021Downgrade
Akero Therapeutics, Inc. (AKRO) was downgraded to D from D+ on 7/29/2021 due to a decline in the total return index and volatility index.
Akero Therapeutics, Inc. (AKRO) was downgraded to D from D+ on 7/29/2021 due to a decline in the total return index and volatility index.
D
Sell
7/2/2021Upgraded
Akero Therapeutics, Inc. (AKRO) was upgraded to D+ from D on 7/2/2021 due to an increase in the valuation index.
Akero Therapeutics, Inc. (AKRO) was upgraded to D+ from D on 7/2/2021 due to an increase in the valuation index.
D
Sell
6/17/2021Downgrade
Akero Therapeutics, Inc. (AKRO) was downgraded to D from D+ on 6/17/2021 due to a decline in the valuation index and total return index.
Akero Therapeutics, Inc. (AKRO) was downgraded to D from D+ on 6/17/2021 due to a decline in the valuation index and total return index.
D
Sell
5/14/2021Upgraded
Akero Therapeutics, Inc. (AKRO) was upgraded to D+ from D on 5/14/2021 due to an increase in the total return index, valuation index and solvency index. The quick ratio increased from 20.47 to 24.66.
Akero Therapeutics, Inc. (AKRO) was upgraded to D+ from D on 5/14/2021 due to an increase in the total return index, valuation index and solvency index. The quick ratio increased from 20.47 to 24.66.
D
Sell
7/1/2020Upgraded
Akero Therapeutics, Inc. (AKRO) was upgraded to D from D- on 7/1/2020 due to a substantial increase in the growth index and solvency index. Earnings per share increased from -$0.5509 to -$0.4171, EBIT increased 23.69% from -$16.22M to -$12.38M, and the quick ratio increased from 14.56 to 15.12.
Akero Therapeutics, Inc. (AKRO) was upgraded to D from D- on 7/1/2020 due to a substantial increase in the growth index and solvency index. Earnings per share increased from -$0.5509 to -$0.4171, EBIT increased 23.69% from -$16.22M to -$12.38M, and the quick ratio increased from 14.56 to 15.12.
D
Sell
3/2/2020Upgraded
Akero Therapeutics, Inc. (AKRO) was upgraded to D- from E on 3/2/2020 due to an increase in the total return index and valuation index.
Akero Therapeutics, Inc. (AKRO) was upgraded to D- from E on 3/2/2020 due to an increase in the total return index and valuation index.
E
Sell
2/5/2020Downgrade
Akero Therapeutics, Inc. (AKRO) was downgraded to E from E+ on 2/5/2020 due to a decline in the valuation index.
Akero Therapeutics, Inc. (AKRO) was downgraded to E from E+ on 2/5/2020 due to a decline in the valuation index.
E
Sell
1/21/2020Upgraded
Akero Therapeutics, Inc. (AKRO) was upgraded to E+ from E on 1/21/2020 due to a noticeable increase in the volatility index and valuation index.
Akero Therapeutics, Inc. (AKRO) was upgraded to E+ from E on 1/21/2020 due to a noticeable increase in the volatility index and valuation index.
E
Sell
12/17/2019Downgrade
Akero Therapeutics, Inc. (AKRO) was downgraded to E from E+ on 12/17/2019 due to a noticeable decline in the volatility index, valuation index and total return index.
Akero Therapeutics, Inc. (AKRO) was downgraded to E from E+ on 12/17/2019 due to a noticeable decline in the volatility index, valuation index and total return index.
E
Sell
12/2/2019Upgraded
Akero Therapeutics, Inc. (AKRO) was upgraded to E+ from E on 12/2/2019 due to a noticeable increase in the total return index, efficiency index and valuation index.
Akero Therapeutics, Inc. (AKRO) was upgraded to E+ from E on 12/2/2019 due to a noticeable increase in the total return index, efficiency index and valuation index.
E
Sell
9/13/2019None
Akero Therapeutics, Inc. (AKRO) was downgraded to E from U on 09/13/2019.
Akero Therapeutics, Inc. (AKRO) was downgraded to E from U on 09/13/2019.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
